V2X secures navy contract for Marine Corps KC-130J infrared countermeasures
V2X (NYSE:VVX) has been awarded a contract by the U.S. Navy’s Naval Air Systems Command (NAVAIR) to support the Large Aircraft Infrared Countermeasures (LAIRCM) program.
V2X (NYSE:VVX) has been awarded a contract by the U.S. Navy’s Naval Air Systems Command (NAVAIR) to support the Large Aircraft Infrared Countermeasures (LAIRCM) program.
Bitcoin Depot (NASDAQ:BTM) has filed for voluntary Chapter 11 bankruptcy protection to facilitate an orderly wind-down of its business and a sale of its corporate assets.
Philips (NYSE:PHG), in partnership with healthcare technology firms Cuviva and Vingmed, has been selected by Region Stockholm to implement a large-scale hospital-at-home program.
Edible Garden (NASDAQ:EDBL) reported strong top-line revenue growth for the first quarter of 2026, driven by retail expansion and broader consumer adoption of its product portfolio, even as heavy capital deployment for its beverage infrastructure weighed on near-term profitability.
Arrive AI (NASDAQ:ARAI), a company developing AI-powered autonomous vehicle and robotics solutions, announced its first-quarter 2026 financial results and provided an operational update.
RenX Enterprises (NASDAQ:RENX) reported strong sequential revenue expansion for the first quarter of 2026, driven by higher utilization across its contracted hauling agreements and accelerating bulk material sales, even as advanced technology integration costs left consolidated bottom-line metrics in a deficit.
Creative Realities (NASDAQ:CREX) reported a significant increase in top-line revenue for the first quarter of fiscal 2026, driven primarily by the financial integration of its Cineplex Digital Media acquisition, even as margin compression and one-time structural charges pulled bottom-line metrics into a deficit.
Polish lawmakers have approved a long-debated cryptocurrency bill as the country moves closer to the European Union’s Markets in Crypto-Assets regulation.
Palvella Therapeutics (NASDAQ:PVLA) reported positive clinical data from its Phase 2 TOIVA trial evaluating its proprietary topical formulation of rapamycin, detailing significant therapeutic benefits for patients suffering from rare vascular skin disorders.
Thorchain has suffered an estimated $10 million to $11 million exploit after attackers manipulated its vault churn process across several major blockchains.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
